About the BRDG-SPAN Program
The National Institutes of Health BRDG-SPAN Pilot Program (the Biomedical Research, Development, and Growth to Spur the Acceleration of New Technologies Pilot Program (RC3) is supported by funds provided to the NIH under the American Recovery & Reinvestment Act of 2009, a component of the Federal Stimulus Package. The purpose of this pilot program is to accelerate the transition of research innovations and technologies toward the development of products or services that will improve human health, help advance the mission of NIH and its Institutes and Centers (ICs), and create significant value and economic stimulus. The BRDG-SPAN pilot is intended to help address the funding gap, often called the "Valley of Death", between innovative promising research and development (R&D) and transitioning those innovations to the market, by contributing to the critical funding needed by applicants to carry out later stage research activities and to pursue the next appropriate milestone(s) necessary to move a product/technology along a promising commercialization pathway. This program also aims to foster partnerships among a variety of research and development (R&D) collaborators.
About Cato BioVentures (HQ: Durham, NC with locations worldwide)
Cato BioVentures is the venture capital affiliate of Cato Research. For over 20 years, Cato BioVentures has assisted entrepreneurs in building successful life science companies. Cato BioVentures invests its CRO Service Capital™ in innovative technologies, therapeutics, medical devices, and platform tools, offering promising life science companies immediate access to a broad range of essential CRO services on a noncash basis. Access to these time-critical CRO services enables management to achieve key value-added development and regulatory milestones with less reliance on other sources of capital. Cato BioVentures has several offices in the
|SOURCE Advanced Pain Remedies; Cato BioVentures|
Copyright©2010 PR Newswire.
All rights reserved